$0.550
+0.206 (+37.50%)At close
ESLA Comparative Benchmarking
In the context of the broader market, ESLA competes directly with industry leaders such as QNTM and MRKR. With a market capitalization of $23.92M, it holds a significant position in the sector. When comparing efficiency, ESLA's gross margin of N/A stands against QNTM's N/A and MRKR's N/A. Such benchmarking helps identify whether Estrella Immunopharma Inc is trading at a premium or discount relative to its financial performance.
Estrella Immunopharma Inc Financial Performance
Estrella Immunopharma has reported consistent losses, with a net income of -2,302,339 USD in Q2 2026 and an EPS of -0.05. The company has a current ratio of 0.20, indicating liquidity issues.
Financials
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.